NEWARK, N.J. (AP) — A biopharmaceutical firm will pay more than $7.5 million to resolve claims it paid kickbacks to doctors to persuade them to prescribe its fentanyl-based drug Abstral, federal prosecutors said.
The settlement with Galena Biopharma was announced Friday.
Prosecutors said the allegations arose from a whistleblower lawsuit. The person who filed the suit will receive more than $1.2 million from the settlement.
The kickbacks included more than 85 free meals to doctors and staff from a "high-prescribing" medical practice and paying various doctors a $5,000 honoraria and speakers $6,000 along with expenses to attend an "advisory board" that was planned and attended by the Galena sales staff, prosecutors said.
"This global, civil-only resolution represents the best possible outcome for Galena, with no exclusion from federal programs and no corporate integrity agreement obligations," Gary Giampetruzzi, a lawyer for the company, said in a statement on Saturday. "Galena is able to move forward with a non-criminal resolution and focus on its mission of developing life-changing hematology and oncology therapeutics."
Before you make your next trade, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.
They believe these five stocks are the five best companies for investors to buy now...
See The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report